Bristol-Myers Squibb Co. (NYSE: BMY) closed the day trading at $49.12 down -2.33% from the previous closing price of $50.29. In other words, the price has decreased by -$1.17 from its previous closing price. On the day, 11770374 shares were traded.
Ratios:
For a better understanding of BMY, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.07 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.87. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.43. In the meantime, Its Debt-to-Equity ratio is 1.41 whereas as Long-Term Debt/Eq ratio is at 1.30.
On February 06, 2024, Redburn Atlantic Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $77 to $54.
BofA Securities Downgraded its Buy to Neutral on January 03, 2024, whereas the target price for the stock was revised from $68 to $60.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 05 ’23 when BOERNER CHRISTOPHER S. bought 2,000 shares for $49.78 per share. The transaction valued at 99,560 led to the insider holds 82,672 shares of the business.
BOERNER CHRISTOPHER S. bought 3,071 shares of BMY for $150,049 on Nov 28 ’23. The Chief Executive Officer now owns 79,384 shares after completing the transaction at $48.86 per share. On Nov 20 ’23, another insider, Samuels Theodore R. II, who serves as the Director of the company, bought 8,500 shares for $49.81 each. As a result, the insider paid 423,385 and bolstered with 35,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMY now has a Market Capitalization of 99.55B and an Enterprise Value of 128.74B. As of this moment, Bristol-Myers’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.73, and their Forward P/E ratio for the next fiscal year is 6.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.21 while its Price-to-Book (P/B) ratio in mrq is 3.37. Its current Enterprise Value per Revenue stands at 2.86 whereas that against EBITDA is 6.65.
Stock Price History:
Over the past 52 weeks, BMY has reached a high of $70.93, while it has fallen to a 52-week low of $47.58. The 50-Day Moving Average of the stock is 51.16, while the 200-Day Moving Average is calculated to be 54.97.
Shares Statistics:
Over the past 3-months, BMY traded about 16.13M shares per day on average, while over the past 10 days, BMY traded about 10.96M shares per day. A total of 2.03B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.08% of the company’s shares, while institutions hold 78.24% stake in the company. Shares short for BMY as of Mar 28, 2024 were 35.12M with a Short Ratio of 2.18, compared to 32.65M on Feb 29, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.73% and a Short% of Float of 1.73%.
Dividends & Splits
BMY’s forward annual dividend rate is 2.34, up from 2.31 a year ago. Against a Trailing Annual Dividend Yield of 4.59%, it implies a Forward Annual Dividend Yield of 4.89%. The stock’s 5-year Average Dividend Yield is 3.22. The current Payout Ratio is 59.82% for BMY, which recently paid a dividend on May 01, 2024 with an ex-dividend date of Apr 04, 2024. Stock splits for the company last occurred on Aug 07, 2001 when the company split stock in a 1000000:951777 ratio.
Earnings Estimates
Current recommendations for the stock of the company come from 11 analysts. On average, analysts expect EPS of $1.49 for the current quarter, with a high estimate of $1.8 and a low estimate of $1.2, while EPS last year was $2.05. The consensus estimate for the next quarter is $1.63, with high estimates of $1.79 and low estimates of $1.54.
Analysts are recommending an EPS of between $6.6 and $5.97 for the fiscal current year, implying an average EPS of $6.33. EPS for the following year is $6.53, with 23 analysts recommending between $7.22 and $5.27.
Revenue Estimates
15 analysts predict $10.54B in revenue for the current quarter. It ranges from a high estimate of $10.81B to a low estimate of $10.26B. As of the current estimate, Bristol-Myers Squibb Co.’s year-ago sales were $11.34B, an estimated decrease of -7.00% from the year-ago figure.
A total of 24 analysts have provided revenue estimates for BMY’s current fiscal year. The highest revenue estimate was $43.04B, while the lowest revenue estimate was $41.82B, resulting in an average revenue estimate of $42.35B. In the same quarter a year ago, actual revenue was $41.44B, up 2.20% from the average estimate. Based on 23 analysts’ estimates, the company’s revenue will be $42.77B in the next fiscal year. The high estimate is $44.19B and the low estimate is $41.59B. The average revenue growth estimate for next year is up 1.00% from the average revenue estimate for this year.
